Firstly, thank you so much for your understanding with our postponement to 7-9 September. With the WHO declaring this novel coronavirus as a  pandemic, we feel it is our duty to still share, engage and educate our community on SARS-CoV-2.
Discover our future and past presentations on some of the most interesting event topics.

Thursday 16th April 

4pm BST/11am EST  

Larry Lamb, CEO, Incysus - Webinars - Advanced Therapies 2020

Biologic Correlative Studies as Potential Predictors of Efficacy for Innate Lymphocyte Therapies
  • Survival and disease progression are the best indices of effectiveness in standard of care plus therapies, but is there more that can be done along the way?
  • Recovery of normal immune cell number, diversity, phenotype, and function is a strong predictor for patients achieving continuing remission
  • This presentation will examine models of tumor genomics, quality of cell therapy graft material pre and post-manufacturing, and the process of immune recovery and function following treatment
Larry Lamb, CSO, Incysus



Troels Jordansen - Webinars - Advanced Therapies 2020

Building your own closed manufacturing system 
  • Hear about how one start-up company successfully built a closed production system 
  • Is it affordable?
  • What are some of the pitfalls?
Troels Jordansen, CEO,  Glycostem Therapeutics    

Bobby Gaspar, CEO,  Orchard Therapeutics - Webinars - Advanced Therapies 2020

Imagining Limitless Possibilities: The Future of Hematopoietic Stem Cell Gene Therapies
  • Understanding the power and versatility of hematopoietic stem cells
  • Reviewing learnings to date about the development and use of hematopoietic stem cell gene therapies
  • Envisioning potential future applications for this platform  
Bobby Gaspar, CEO,  Orchard Therapeutics




Google Play


App Store



“I wanted to thank you for giving me the opportunity to be a part of this wonderful conference. I enjoyed the presentations very much and I hope I gave a little back in the round tables and the panels I participated in.”


VP Development, Pluristem Therapeutics